GLP-1 Drugs Aren't Just for Weight Loss — Here's the Bigger Picture

Semaglutide reduced cardiovascular events by 20% in people without diabetes in the SELECT trial. GLP-1 receptor agonists were developed for diabetes, but the receptor sits in the heart, brain, liver, kidneys, and immune cells. Emerging data suggests benefits in NASH, Alzheimer's risk, kidney protection, and even addiction behaviour modification.